Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Muscle Growth
Soluble myostatin / activin trap — recombinant decoy of the activin IIB receptor.
Peptide B
Muscle Growth
Single-chain relaxin peptide analog with anti-fibrotic and cardioprotective activity.
Typical vial
1 mg
Typical dose
Per kg dosing mcg
Half-life
~10-15 days (Fc-fusion)
FDA status
Not FDA approved. Clinical development halted in 2011 after …
Typical vial
2 mg
Typical dose
1000-2000 mcg
Half-life
~2-3 hours
FDA status
Not FDA approved.
ACE-031 effects
B7-33 effects
ACE-031 side effects
B7-33 side effects
ACE-031 dosing ranges
Research / muscle volume increase
0.5-3 mg/kg · IV or SubQ every 2-4 weeks · Per protocol
B7-33 dosing ranges
Research / anti-fibrotic
1-2 mg · Daily (SubQ or IV in preclinical work) · Per research protocol
ACE-031: Soluble myostatin / activin trap — recombinant decoy of the activin IIB receptor. Typical dose Per kg dosing mcg. B7-33: Single-chain relaxin peptide analog with anti-fibrotic and cardioprotective activity. Typical dose 1000-2000 mcg. Both fall under the Muscle Growth category.
Stacking ACE-031 with B7-33 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
ACE-031 is typically dosed: IV or SubQ every 2-4 weeks for Research / muscle volume increase. B7-33 is typically dosed: Daily (SubQ or IV in preclinical work) for Research / anti-fibrotic.
ACE-031: Not FDA approved. Clinical development halted in 2011 after capillary leak observations. B7-33: Not FDA approved.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free